



Company Overview

OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet patient needs and establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, one of the nation's largest clinical laboratories, with a core genetic testing business and a 300 person sales and marketing team to drive growth and leverage new products, including 4KScore® prostate cancer test and the Claros® 1 point-of-care device, which is capable of in office measurement of PSA within 10 minutes.

Our pharmaceutical business features Rayaldee®, an FDA approved treatment for SHPT in stage 3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency, which was launched in November 2016. Besides nephrology, we have strategic focus on the development of diagnostic and therapeutic agents in urology and endocrinology. Pipelines using the same proprietary platforms, such as the long acting CTP, Reverse-PEGylation, and the Claros® 1 immunoassay system are in various stage of discovery, lead molecule validation, early clinical, clinical, and expanded post marketing indications. We invest in development of low risk proven therapeutic targets and utilize validated technology to expand our diagnostic test menu for unmet medical needs.

We have production and distribution assets abroad, several strategic investments, and an active business development strategy. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and the pursuit of complementary acquisitions and investments.

Stock Overview

Symbol	OPK
Exchange	Nasdaq
Shares OS	559,473,568
Market Cap	\$1.12B
Last Price	\$2.00
52-Week Range	\$1.73 - \$6.40

06/17/2019 04:00 PM EDT

Investor Relations

LHA
Miriam Weber Miller
T: 212-838-3777
mmiller@lhai.com

Management Team

Phil Frost

CEO and Chairman

Jane Hsiao

CTO and Vice Chairman

Steve Rubin

Executive Vice President, Administration

Adam Logal

Senior Vice President and CFO

Jon R. Cohen

Senior Vice President, OPKO Health; Executive Chairman, BioReference Laboratories

Geoff Monk

President, BioReference Laboratories

Ben Solomon

Managing Director, GeneDx

Charles Bishop

CEO of OPKO Renal

Tony Cruz

President of Transition Therapeutics

Hans Berner

President, OPKO Health Iberoamerica

Kate Inman

General Counsel

Jane Pine Wood

CLO, BioReference Laboratories

Patsy Carney

CEO, Eirgen Pharma

Arie Gutman

President of API

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137

[OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results](#)

May 7 2019, 12:00 AM EDT

[OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019](#)

Apr 30 2019, 12:00 AM EDT

[OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial](#)

Apr 12 2019, 12:00 AM EDT

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

